Patients with chronic myeloid leukemia and coronavirus disease 2019 in the Omicron era
Annals of Hematology · 2023
DOI: 10.1007/s00277-023-05413-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, 2023. Verfasst von Feiyang Qi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Ke…. Hauptthemen laut MEDLINE: COVID-19, Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
To explore the prevalence and severity of COVID-19 and the mental health during the Omicron pandemic in patients with chronic myeloid leukemia (CML), a cross-sectional survey from 2609 respondents with CML was performed. A total of 1725 (66%) reported that they had COVID-19 during this period. Among them, 1621 (94%) were mild; 97 (6%), moderate; 7 (0.4%), severe; and 0, critical or death. Four hundred three (15%), 199 (8%), and 532 (20%) had moderate to severe depression, anxiety, and distress, respectively. Eight hundred ninety (34%), 667 (26%), and 573 (22%), avoidance, intrusion, and hyper-arousal, respectively. In multivariate analyses, longer TKI-therapy duration was significantly associated with a lower prevalence of COVID-19 (odds ratio [OR] = 0.98; 95% confidence interval [CI], 0.95, 0.99; p = 0.043); however, living in urban areas (OR = 1.6 [1.3, 2.0]; p < 0.001) and having family members with COVID-19 (OR = 18.6 [15.1, 22.8]; p < 0.001), a higher prevalence of COVID-19. Increasing age (OR = 1.2 [1.1, 1.4]; p = 0.009), comorbidity(ies) (OR = 1.7 [1.1, 2.7]; p = 0.010), and multi-TKI-resistant patients receiving 3rd-generation TKIs or investigational agents (OR = 2.2 [1.2, 4.2]; p = 0.010) were significantly associated with moderate or severe COVID-19. Female, comorbidity(ies), unvaccinated, and moderate or severe COVID-19 were significantly associated with almost all adverse mental health consequences; increasing age or forced TKI dose reduction because of various restriction during the pandemic, moderate to severe distress, avoidance, or intrusion; however, mild COVID-19, none or mild anxiety, distress, avoidance, or intrusion. In conclusion, shorter TKI-therapy duration, increasing age, comorbidity(ies), or multi-TKI-resistant patients receiving 3rd-generation TKIs or investigational agents had a higher prevalence of COVID-19 or higher risk of moderate or severe disease in patients with CML; increasing age, female, comorbidity(ies), forced TKI dose reduction due to the pandemic, moderate or severe COVID-19, unvaccinated, a higher likelihood of worse mental health.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, No. 11 Xizhim…
- Peking University People's Hospital, Qingdao, China.
- Peking University People's Hospital, Qingdao, China. jiangqian@medmail.com.cn.
- Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China. jiangqian@medmail.com.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Qi, F., Bao, M., Gao, H., Zhang, X., Zhao, S., Wang, C., Li, W., & Jiang, Q. (2023). Patients with chronic myeloid leukemia and coronavirus disease 2019 in the Omicron era. Annals of Hematology. https://doi.org/10.1007/s00277-023-05413-0
Vancouver
Qi F, Bao M, Gao H, Zhang X, Zhao S, Wang C, et al. Patients with chronic myeloid leukemia and coronavirus disease 2019 in the Omicron era. Annals of Hematology. 2023. doi:10.1007/s00277-023-05413-0
BibTeX
@article{Qi2023,
author = {Qi, Feiyang and Bao, Mei and Gao, Hanlin and Zhang, Xiaoshuai and Zhao, Shasha and Wang, Chenglei and Li, Wenwen and Jiang, Qian},
title = {Patients with chronic myeloid leukemia and coronavirus disease 2019 in the Omicron era},
journal = {Annals of Hematology},
year = {2023},
doi = {10.1007/s00277-023-05413-0}
}
EUVIMED